Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Biomarkers (1)
- LDH (normal <246) - Lactic Acid Dehydrogenase (LDH) (normal <246) (phv00261104.v1.p1)
Demographics (2)
- Age - Age of participant (phv00261091.v1.p1)
- Sex - Gender (phv00261093.v1.p1)
Disease Events (12)
- AFFECTION_STATUS - Case control status of the subject (phv00261083.v1.p1)
- BRAF/NRAS status - BRAF/NRAS mutation status (phv00261105.v1.p1)
- Clinical_Benefit - Clinical benefits (phv00261095.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00261112.v1.p1)
- IS_TUMOR - Tumor status (phv00261111.v1.p1)
- M stage - M stage (phv00261100.v1.p1)
- OS_yr - Overall Survival (phv00261106.v1.p1)
- Primary Melanoma type - Primary melanoma type (phv00261099.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00261113.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00261114.v1.p1)
- TUMOR_GRADE - Tumor grade of sample (phv00261116.v1.p1)
- TUMOR_STAGE - Tumor stage of sample (phv00261115.v1.p1)
Other (26)
- Alive - Living status (phv00261092.v1.p1)
- ANALYTE_TYPE - Analyte type (phv00261110.v1.p1)
- Biopsy pre or post ipi - Biopsy pre or post Ipilimumab treatment (phv00261107.v1.p1)
- Biopsy type - Biopsy type (phv00261098.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00261109.v1.p1)
- Cohort - Cohort (phv00261090.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00261080.v1.p1)
- Drug - Drug (phv00261102.v1.p1)
- GENOTYPING_CENTER - Name of the center which conducted genotyping (phv00261118.v1.p1)
- Ipi_dosing - Ipilimumab dosing (phv00261101.v1.p1)
- Largest Dimension (cm) - Largest dimension (cm) (phv00261097.v1.p1)
- Priors - Cytotoxic chemotherapy or IL-2 in the metastatic setting (phv00261094.v1.p1)
- Response duration (weeks) - Response duration (weeks) (phv00261103.v1.p1)
- SAMPLE_ID - De-identified sample ID (phv00261108.v1.p1)
- SAMPLE_ID - Sample ID (phv00261085.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00261086.v1.p1)
- SAMPLE_USE - Sample use. Seq_DNA_SNP: SNP genotypes derived from sequence data; Seq_DNA_WholeExome: Whole exome sequencing (phv00261088.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00261119.v1.p1)
- Site - Site of metastasis (phv00261096.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00261087.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00261082.v1.p1)
- SUBJECT_ID - De-identified subject ID (phv00261089.v1.p1)
- SUBJECT_ID - Subject ID (phv00261079.v1.p1)
- SUBJECT_ID - Subject ID (phv00261084.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00261081.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00261117.v1.p1)